You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company, along with Softbank Investment Advisers, is offering a total of 11.5 million shares of its common stock at $84 per share.
The company plans to use the proceeds for general product R&D, for reimbursement studies in the US, and for preparation for potential COVID-19 testing.
BD has also granted the offerings' underwriters an option to purchase up to an additional $450 million of common stock and depositary shares.
The firm said it will use the funds for general corporate purposes, which may include investment and acquisitions, working capital, and debt repayment.
The net proceeds will support continued product development, research, product commercialization, working capital, and other general corporate purposes.
The firm said it would use the funds for general corporate purposes, including potential future acquisitions, capital expenditures, and investments or loans.
GenMark said it intends to use the proceeds for general corporate purposes that may include an expansion of its menu and increasing its manufacturing capacity.
The test will be included in the World Health Organizations list of prequalified in vitro diagnostics and UN agencies will be able to procure it.
The company said it intends to use the proceeds for general corporate purposes and to repay borrowings under its term loan facility.
The firm will offer 4.7 million shares of its stock at $2.27 per share. Proceeds will go toward the development and commercialization of its tests.